Despite the surprise departure of CEO David Horn Solomon at the end of 2019, Silence Therapeutics PLC of the UK says it is in good shape and has unveiled a deal with Takeda Pharmaceutical Co. Ltd. as well as plans to set up a US subsidiary.
The pact with Takeda, worth “single-digit million dollars of research funding," will see the Japanese major use the London-based gene...







